Direct-to-consumer GLP-1s are rising fast
How can plan sponsors balance member needs with plan goals?
More access. More pressure. More unknowns.
GLP-1s are a growing category and there’s no longer just one way to access them. Members can get treatment options through their pharmacy benefit or turn to direct-to-consumer (DTC) options outside their benefit. For plan sponsors, that creates new trade-offs around access, affordability and outcomes.
Up to 30M Americans may be using GLP-1s by the end of the decade.
Looking beyond easy access
Convenience and lower upfront costs of DTC GLP-1s can be appealing. But they don’t always tell the full story. Costs can rise over time. Support can vary. And outcomes may be hard to predict. The difference between on-benefit and off-benefit access can directly impact:
- Cost predictability
- Clinical support
- Long-term outcomes
What’s the right balance?
DTC GLP-1s aren’t going away. But how do they stack up against traditional coverage?
In The rapid rise of direct-to-consumer GLP-1s: Helping you evaluate access, affordability and the impact of coverage decisions, Joshua Fredell, Senior Vice President & Head of PBM & Specialty Product Innovation, breaks down:
- How different access models work
- Which trade-offs matter most
- What it means for your strategy
